The brand name for bempedoic acid is Nexletol [1]. It is also available in combination with ezetimibe under the brand name Nexlizet [1].
What is Nexletol prescribed for?
Nexletol is prescribed to lower LDL cholesterol in adults who have heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who are on maximally tolerated statin therapy [1].
How does bempedoic acid work?
Bempedoic acid is an inhibitor of ATP citrate lyase (ACL) [1]. By inhibiting ACL, it reduces cholesterol synthesis in the liver [1]. It is a prodrug that is activated in the liver [1].
When did Nexletol become available?
Nexletol was approved by the U.S. Food and Drug Administration (FDA) in February 2020 [1].
What is the difference between Nexletol and Nexlizet?
Nexletol contains only bempedoic acid, while Nexlizet is a combination product containing both bempedoic acid and ezetimibe [1]. Both medications are used to lower LDL cholesterol [1].
Are there any patents for bempedoic acid?
Yes, there are patents covering bempedoic acid and its uses. DrugPatentWatch.com tracks patent information for pharmaceuticals, including bempedoic acid [2].
What are the potential side effects of bempedoic acid?
Common side effects of bempedoic acid include upper respiratory tract infection, muscle spasms, back pain, and increased levels of enzymes in the blood called creatine phosphokinase and alanine aminotransferase [1].
Where can I find more information on bempedoic acid patents?
DrugPatentWatch.com provides detailed patent information for drugs like bempedoic acid [2].
Sources
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/